What's The BUZZ?

Market News, Products, Services, and Trends

Advertisement
QI Medical

Dr. Reddy’s Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

Hyderabad, India and Princeton, NJ, USA. January 27, 2023 – Dr. Reddy’s Laboratories Ltd. (BSE:500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Dr. Reddy’s Difluprednate Ophthalmic Emulsion 0.05%, a therapeutic generic equivalent to Durezol® (Difluprednate Ophthalmic Emulsion 0.05%) in the U.S. market, following the approval by the U.S. Food and Drug Administration (USFDA).

The Durezol® brand and generic had U.S. sales of approximately $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA*.

Dr. Reddy’s Difluprednate Ophthalmic Emulsion 0.05% is available in 5 ml bottles in case packs of 24.

Please click here for full prescribing information: https://drreddys.com/pi/PI_Difluprednate-Opthalmic.pdf.

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd. News & Announcements

Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

10-rxinsider-staff

Posted by: RXinsider Staff

RXinsider is a multimedia publishing and technology company offering print publications, digital platforms, events, and content creation services to the B2B pharmacy market.

SUBSCRIBE

Name
Subscription Choices
Checkboxes

Request information from Dr. Reddy’s Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

Name
Address
Subscribe